+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjogren's syndrome



Treatment of xerostomia with polymer-based saliva substitutes in patients with Sjogren's syndrome



Arthritis and Rheumatism 39(1): 57-63



Objective: To determine the efficacy of 3 types of polymer-based saliva substitutes in reducing oral dryness in patients with Sjogren's syndrome (SS). Methods: Subjective efficacy of 3 different saliva substitutes (determined by self-administered questionnaire) was evaluated in a double-blind, placebo-controlled trial in 43 patients with primary and secondary SS. High-viscosity versus low-viscosity xanthan gum-based saliva substitutes were also compared in 33 SS patients. Salivary flow rates (SFR) were determined to examine correlations between the SFR and the subjective efficacy of the saliva substitute. Results: Neither the saliva substitutes nor the placebo was truly effective. Preference for a particular saliva substitute over placebo was equally distributed among the 3 types of substitutes. The SFR of patients who preferred polyacrylic acid-based saliva substitutes was lower than that in patients who preferred the porcine mucin-based substitute (P lt 0.05). Patients whose oral dryness was reduced by low-viscoelastic substitutes had a low stimulated SFR ( lt 0.20 ml/minute; P lt 0.05). Conclusion: The optimal properties of a saliva substitute are not the same for all patients with SS, but are dependent on such parameters as the individual SFR. Thus, to determine the best saliva substitute for a particular patient, it is necessary to have the patient try a number of substitutes of different viscoelastic properties.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009674488

Download citation: RISBibTeXText

PMID: 8546739


Related references

The use of a saliva substitute as treatment for xerostomia in Sjögren's syndrome--a case report. Oral Surgery Oral Medicine and Oral Pathology 52(4): 384-386, 1981

Lecithin-based emulsions for potential use as saliva substitutes in patients with xerostomia--viscoelastic properties. International Journal of Pharmaceutics 456(2): 560-568, 2013

Saliva substitutes not very popular in patients with Sjogren Syndrome. Nederlands Tijdschrift Voor Tandheelkunde 120(1): 4, 2013

Cytokine concentrations in stimulated whole saliva among patients with primary Sjögren's syndrome, secondary Sjögren's syndrome, and patients with primary Sjögren's syndrome receiving varying doses of interferon for symptomatic treatment of the condition: a preliminary study. Clinical Oral Investigations 5(2): 133-135, 2001

Use of saliva substitutes in patients with xerostomia. Schweizer Monatsschrift für Zahnmedizin 112(10): 1037-1058, 2002

Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases. Rheumatology 50(7): 1288-1292, 2011

Saliva substitutes for the treatment of radiation-induced xerostomia--a review. Supportive Care in Cancer 17(11): 1331-1343, 2009

Different saliva substitutes for treatment of xerostomia following radiotherapy. A prospective crossover study. Strahlentherapie und Onkologie 181(4): 231-236, 2005

Cevimeline gargle for the treatment of xerostomia in patients with Sjögren's syndrome. Annals of the Rheumatic Diseases 63(6): 749, 2004

Treatment of xerostomia in patients with primary Sjögren's syndrome with sulfarlem. Scandinavian Journal of Rheumatology. Supplement 61: 250-252, 1986

Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: A randomized trial. Archives of Internal Medicine 162(11): 1293-1300, 2002

Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome. Annals of the Rheumatic Diseases 57(8): 464-469, 1998

Usefulness of oral pilocarpin therapy in the treatment of xerostomia and xerophthalmia in patients with primary Sjögren's syndrome. Medicina Clinica 122(7): 253-255, 2004

Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögren's syndrome. Journal of Interferon and Cytokine Research 18(4): 255-262, 1998

Salivary stimulants and saliva substitutes are equally effective in terms of patient-perceived comfort in patients with xerostomia (UT CAT #2188). Texas Dental Journal 129(6): 586, 2012